CN102177255B - 利用foxo3a的多态性和单元型预测和促进健康衰老和长寿的方法 - Google Patents

利用foxo3a的多态性和单元型预测和促进健康衰老和长寿的方法 Download PDF

Info

Publication number
CN102177255B
CN102177255B CN200980140170.7A CN200980140170A CN102177255B CN 102177255 B CN102177255 B CN 102177255B CN 200980140170 A CN200980140170 A CN 200980140170A CN 102177255 B CN102177255 B CN 102177255B
Authority
CN
China
Prior art keywords
allele
foxo3a
locus
polymorphism
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980140170.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102177255A (zh
Inventor
蒂莫斯·艾奇逊·唐隆
布拉德利·约翰·威尔科克斯
戴维·J·库尔巴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KUAKINI MEDICAL CT
Original Assignee
KUAKINI MEDICAL CT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102177255(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KUAKINI MEDICAL CT filed Critical KUAKINI MEDICAL CT
Publication of CN102177255A publication Critical patent/CN102177255A/zh
Application granted granted Critical
Publication of CN102177255B publication Critical patent/CN102177255B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/125Allele specific primer extension
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN200980140170.7A 2008-08-10 2009-08-10 利用foxo3a的多态性和单元型预测和促进健康衰老和长寿的方法 Active CN102177255B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8772208P 2008-08-10 2008-08-10
US61/087,722 2008-08-10
PCT/US2009/053307 WO2010019519A2 (en) 2008-08-10 2009-08-10 Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity

Publications (2)

Publication Number Publication Date
CN102177255A CN102177255A (zh) 2011-09-07
CN102177255B true CN102177255B (zh) 2015-12-16

Family

ID=41669598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980140170.7A Active CN102177255B (zh) 2008-08-10 2009-08-10 利用foxo3a的多态性和单元型预测和促进健康衰老和长寿的方法

Country Status (9)

Country Link
US (3) US20110212447A1 (https=)
EP (1) EP2324127B1 (https=)
JP (1) JP5814119B2 (https=)
KR (2) KR101649541B1 (https=)
CN (1) CN102177255B (https=)
AU (1) AU2009282172B2 (https=)
CA (1) CA2733597C (https=)
DK (1) DK2324127T3 (https=)
WO (1) WO2010019519A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110212447A1 (en) * 2008-08-10 2011-09-01 Timothy Atchison Donlon Method of Using FOXO3A Polymorphisms and Haplotypes to Predict and Promote Healthy Aging and Longevity
US8990135B2 (en) * 2010-06-15 2015-03-24 The Regents Of The University Of Michigan Personalized health risk assessment for critical care
CN103233001B (zh) * 2012-06-25 2016-11-02 西北农林科技大学 秦川牛FoxO1基因单核苷酸多态性分子标记的检测方法与应用
KR102017562B1 (ko) * 2013-03-13 2019-09-03 (주)아모레퍼시픽 미백 효능 물질의 스크리닝 방법
WO2017062751A1 (en) * 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance
WO2018183353A1 (en) * 2017-03-27 2018-10-04 Cardax Pharma, Inc. Small molecule compounds to support healthy human aging
WO2018209222A1 (en) * 2017-05-12 2018-11-15 Massachusetts Institute Of Technology Systems and methods for crowdsourcing, analyzing, and/or matching personal data
WO2019156591A1 (en) * 2018-02-12 2019-08-15 Limited Liability Company "Gero" Methods and systems for prediction of frailty background
CN111235250A (zh) * 2020-03-31 2020-06-05 中国科学院昆明动物研究所 与健康老龄相关的关键通路及其外周血dna甲基化位点标志物和应用
CN115466321B (zh) * 2022-09-23 2024-03-22 南方医科大学珠江医院 FOXO3a-DRI肽段、其药物组合物及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5710001A (en) 1994-08-12 1998-01-20 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
US5753441A (en) 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
ATE198623T1 (de) 1994-08-12 2001-01-15 Myriad Genetics Inc Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5693473A (en) 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5709999A (en) 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5837495A (en) 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
DE69625678T3 (de) 1995-12-18 2006-11-09 The University Of Utah Research Foundation, Salt Lake City Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
US6673546B2 (en) 2000-08-11 2004-01-06 The Children's Medical Center Corporation Genetic loci indicative of propensity for longevity and methods for identifying propensity for age-related disease
US20040121407A1 (en) 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
DK1413584T3 (da) 2002-10-21 2005-07-04 Axxam S R L Fotoprotein med forbedret bioluminescens
US7932049B2 (en) 2002-12-23 2011-04-26 University Of Massachusetts Methods of identifying longevity modulators and therapeutic methods of use thereof
DE10311769A1 (de) 2003-03-18 2004-09-30 Bayer Healthcare Ag Testmethoden zur Bestimmung der intrazellulären Konzentration zyklischer Nukleotide
WO2005004814A2 (en) 2003-07-02 2005-01-20 Elixir Pharmaceuticals, Inc. Sirt1 and genetic disorders
WO2005007687A1 (en) 2003-07-09 2005-01-27 Dana-Farber Cancer Institute, Inc Compositions and methods for modulating ovarian follicular initiation
JP2005168463A (ja) 2003-12-15 2005-06-30 Chisso Corp カルシウム結合型発光蛋白質の保存方法等
US20060069049A1 (en) 2003-12-29 2006-03-30 President And Fellows Of Harvard College Methods and reagents related to foxo
CA2569079A1 (en) 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
US7622271B2 (en) * 2004-07-26 2009-11-24 University Of Washington Identification of aging genes through large-scale analysis
US20070118398A1 (en) * 2005-11-18 2007-05-24 Flicker Technologies, Llc System and method for estimating life expectancy and providing customized advice for improving life expectancy
JP5292569B2 (ja) * 2006-11-10 2013-09-18 国立大学法人名古屋大学 抗老化転写因子活性化剤及びその利用
US20110212447A1 (en) * 2008-08-10 2011-09-01 Timothy Atchison Donlon Method of Using FOXO3A Polymorphisms and Haplotypes to Predict and Promote Healthy Aging and Longevity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress;Geert J. P. L. Kops et al.;《Nature》;20020919;第419卷(第6904期);316-321 *
impact on disease and mortality at old age.《European Journal of Human Genetics》.2007,第15卷(第3期),294-301. *
Maris Kuningas et al..Haplotypes in the human Foxo1a and Foxo3a genes *
Polymorphisms in FOXO Gene Family and Association Analysis with BMI;Jae-Ryong Kim et al.;《Obesity》;20060228;第14卷(第2期);188-193 *

Also Published As

Publication number Publication date
WO2010019519A3 (en) 2010-05-27
AU2009282172B2 (en) 2016-06-02
JP5814119B2 (ja) 2015-11-17
EP2324127B1 (en) 2015-01-21
CA2733597A1 (en) 2010-02-18
AU2009282172A1 (en) 2010-02-18
CN102177255A (zh) 2011-09-07
KR20160102081A (ko) 2016-08-26
JP2011530312A (ja) 2011-12-22
US20110212447A1 (en) 2011-09-01
HK1158271A1 (en) 2012-07-13
KR20110057147A (ko) 2011-05-31
DK2324127T3 (en) 2015-04-27
US20150337383A1 (en) 2015-11-26
US20130295566A1 (en) 2013-11-07
EP2324127A2 (en) 2011-05-25
CA2733597C (en) 2019-02-26
US12534761B2 (en) 2026-01-27
WO2010019519A2 (en) 2010-02-18
KR101649541B1 (ko) 2016-08-19
EP2324127A4 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
CN102177255B (zh) 利用foxo3a的多态性和单元型预测和促进健康衰老和长寿的方法
Walters et al. A new highly penetrant form of obesity due to deletions on chromosome 16p11. 2
Menezes et al. AXIS inhibition protein 2, orofacial clefts and a family history of cancer
Wheeler et al. Sequential use of transcriptional profiling, expression quantitative trait mapping, and gene association implicates MMP20 in human kidney aging
EP1978107A1 (en) Fto gene polymorphisms associated to obesity and/or type II diabetes
JP6263499B2 (ja) 変形性関節症に関連する状態に対する遺伝的素因の検出
Tsai et al. Sequence variants of ADIPOQ and association with type 2 diabetes mellitus in Taiwan Chinese Han population
WO2013043554A1 (en) Methods for creating recommended dietary regime
AU2015243449A1 (en) Genetic markers associated with chromosomal deletion and duplication syndromes
US20110086796A1 (en) Methods for predicting the development and resolution of acute respiratory distress syndrome
Kurina et al. Sex differences in the genetic basis of morning serum cortisol levels: genome-wide screen identifies two novel loci specific to women
US20030170678A1 (en) Genetic markers for Alzheimer's disease and methods using the same
Carvalho et al. FAM5C contributes to aggressive periodontitis
BR112015017815B1 (pt) Método para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento a base de antipsicótico
TWI351436B (en) Method for detecting a risk of the development of
US10731219B1 (en) Method for preventing progression to metabolic syndrome
HK1158271B (en) Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity
Xu et al. Functional variants of TNFAIP3 are associated with systemic lupus erythematosus in a cohort of Chinese Han population
KR102650359B1 (ko) 약물 과민반응 진단용 snp 및 이를 이용한 진단 방법
Alrfooh DNA methylation signature: as a potential biomarker for addiction and psychiatric disorders
US20100184839A1 (en) Allelic polymorphism associated with diabetes
JP2007517511A (ja) ヒトチオプリンs−メチルトランスフェラーゼ欠損に関連するハプロタイプおよび多型
EP2823054B1 (en) Genetic factors in blood pressure
KR20240061944A (ko) 당뇨병 예측 또는 진단용 kcnq1 snp 마커 및 이의 용도
KR101189839B1 (ko) 아스피린 과민성 천식 진단용 ptger 유전자 패밀리 다형성 마커

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant